Slingshot members are tracking this event:

FDA Approves Celgene's (CELG) REVLIMID in Treating Multiple Myeloma (MM) Following Autologous Stem Cell Transplant (ASCT)

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 22, 2017
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Revlimid, Multiple Myeloma, Autologous Stem Cell Transplant